<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01668498</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-LQ-0110</org_study_id>
    <secondary_id>2010-022938-85</secondary_id>
    <nct_id>NCT01668498</nct_id>
  </id_info>
  <brief_title>Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer</brief_title>
  <official_title>Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of Quality of Life in Patients With Ras-wildtype Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      80 - 90 % of the patients treated with anti-EGFR antibodies (panitumumab or cetuximab)&#xD;
      experience skin toxicity, mostly acne like skin rash.&#xD;
&#xD;
      A standardized treatment of skin rash is neither established as standard arm for clinical&#xD;
      trials nor as guideline for the treatment of skin toxicity in clinical practice. While an&#xD;
      improvement of QoL has been demonstrated for panitumumab and cetuximab in comparison to best&#xD;
      supportive care the data basis for patient related outcomes regarding skin toxicity deriving&#xD;
      from randomized trials is still small.&#xD;
&#xD;
      Recent surveys among German oncologist revealed that physicians are reluctant to use oral&#xD;
      antibiotics as preemptive treatment . Only 19 out of 110 oncologists stated that they are&#xD;
      thinking about using preemptive treatment in patients with acne-like skin rash.&#xD;
&#xD;
      Thus, in the present trial two main questions will be addressed:&#xD;
&#xD;
      (i) Can preemptive treatment with oral doxycycline be replaced by a sequential skin treatment&#xD;
      strategy (i.e. local treatment with erythromycin followed by doxycycline in case of&#xD;
      inefficacy = development of acne) without compromising treatment efficacy of skin toxicity&#xD;
      treatment? (ii) Comparison of general and skin related QoL between both treatment arms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients developing no skin toxicity ≥ grade 2</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage of patients developing no skin toxicity ≥ grade 2 at any time during their first 8-weeks of treatment with panitumumab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Quality of life will be assessed by standardized skin-related (DLQI) and global quality of life (EORTC QLQ C30.&#xD;
For correlation analyses between the different quality of life scores, the non-parametric test according to Spearman will preferably be applied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess Skin toxicity</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assess different skin toxicity grading scales (i.e. NCI CTC v. 4.0; WoMo score; MESTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between skin-related and global quality of life</measure>
    <time_frame>8 weeks</time_frame>
    <description>Description of correlation between skin-related and global quality of life using EORTC-QLQ C30 and SF-36.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late skin toxicity</measure>
    <time_frame>from week 8 to 12</time_frame>
    <description>Describe the development of late skin toxicity after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin-toxicity related dose reductions of panitumumab</measure>
    <time_frame>8 weeks</time_frame>
    <description>Rate of skin-toxicity induced dose reductions (including withdrawal) of panitumumab</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Ras-wildtype Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Erythromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Arm (ARM A) skin- treatment: erythromycin cream 2% daily at bedtime doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2 skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxycyline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Arm (ARM B) skin- treatment:doxycycline 100mg b.i.d. skin moisturizer daily at morning, sunscreen before going outdoors for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythromycin</intervention_name>
    <description>Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.</description>
    <arm_group_label>Erythromycin</arm_group_label>
    <other_name>Aknemycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.</description>
    <arm_group_label>Doxycyline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with wild-type RAS (KRAS and NRAS) status of metastatic colorectal cancer&#xD;
             treatment with panitumumab according to label&#xD;
&#xD;
               -  RAS wild-type tested in&#xD;
&#xD;
               -  KRAS exon 2 (codons 12/13)&#xD;
&#xD;
               -  KRAS exon 3 (codons 59/61)&#xD;
&#xD;
               -  KRAS exon 4 (codons 117/146)&#xD;
&#xD;
               -  NRAS exon 2 (codons 12/13)&#xD;
&#xD;
               -  NRAS exon 3 (codons 59/61)&#xD;
&#xD;
               -  NRAS exon 4 (codons 117/146)&#xD;
&#xD;
          2. treatment with pre-emptive study medication shall begin the day before treatment start&#xD;
             with panitumumab&#xD;
&#xD;
          3. Willingness to cope with biweekly quality of life questionnaires&#xD;
&#xD;
          4. Written Informed consent&#xD;
&#xD;
          5. Aged at least 18 years&#xD;
&#xD;
          6. ECOG Performance Status 0-2&#xD;
&#xD;
          7. Life expectancy of at least 12 weeks&#xD;
&#xD;
          8. Adequate haematological, hepatic, renal and metabolic function parameters:&#xD;
&#xD;
               -  Leukocytes &gt; 3000/mm³&#xD;
&#xD;
               -  ANC ≥ 1500/mm³&#xD;
&#xD;
               -  Platelets ≥ 100,000/mm³&#xD;
&#xD;
               -  Haemoglobin &gt; 9 g/dl&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 x ULN&#xD;
&#xD;
               -  GOT-GPT ≤ 2.5 x ULN (in case of liver metastases GOT / GPT ≤ 5 x ULN)&#xD;
&#xD;
               -  AP ≤ 5 x ULN&#xD;
&#xD;
               -  Magnesium, Calcium and potassium within normal ranges (may be substituted before&#xD;
                  study entry)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject pregnant or breast feeding, or planning to become pregnant within 6 months&#xD;
             after the end of treatment.&#xD;
&#xD;
          2. Subject (male or female) is not willing to use highly effective methods of&#xD;
             contraception (per institutional standard) during treatment and for 6 months (male or&#xD;
             female) after the end of treatment (adequate: oral contraceptives, intrauterine device&#xD;
             or barrier method in conjunction with spermicidal jelly).&#xD;
&#xD;
          3. Serious concurrent diseases&#xD;
&#xD;
          4. On-treatment participation in a clinical study in the period 30 days prior to&#xD;
             inclusion&#xD;
&#xD;
          5. Clinically significant cardiovascular disease in (incl. myocardial infarction,&#xD;
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac&#xD;
             arrhythmia) ≤ 1 year before enrolment.&#xD;
&#xD;
          6. History of interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis or&#xD;
             evidence of interstitial lung disease on baseline chest CT scan.&#xD;
&#xD;
          7. History of HIV infection.&#xD;
&#xD;
          8. Other previous or concurrent malignancy (≤ 5 years prior to enrolment in study) except&#xD;
             non-melanoma skin cancer or cervical carcinoma FIGO stage 0- 1 if the patient is&#xD;
             continuously disease-free&#xD;
&#xD;
          9. Known allergic reactions on panitumumab, doxycycline or erythromycin&#xD;
&#xD;
         10. Previous treatment with anti-cancer agents directed against EGFR (e.g. cetuximab,&#xD;
             panitumumab, erlotinib, gefitinib, lapatinib)&#xD;
&#xD;
         11. Skin rash existing before or due to other reasons than panitumumab treatment&#xD;
&#xD;
         12. Other dermatologic disease that may interfere with correct grading of panitumumab&#xD;
             induced skin rash&#xD;
&#xD;
         13. Parallel treatment with anti-tumor agents other than panitumumab&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Kripp, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>III. Medizinische Klinik, Universitätsmedizin Mannheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim, III. Medizinische Klinik</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.aio-portal.de</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Can preemptive treatment of panitumumab mediated skin</keyword>
  <keyword>toxicity with oral doxycycline be replaced by local treatment with erythromycin?</keyword>
  <keyword>Panitumumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Erythromycin</mesh_term>
    <mesh_term>Erythromycin Estolate</mesh_term>
    <mesh_term>Erythromycin Ethylsuccinate</mesh_term>
    <mesh_term>Erythromycin stearate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

